Lipitor's Patent Cliff and Revenue Drop
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, lost U.S. patent protection in November 2011 after generating peak annual sales over $12 billion in 2006.[1] Generic entry immediately eroded revenue: U.S. sales fell 85% in the first full year post-expiry, from $5.2 billion in 2011 to under $800 million in 2012.[2]
Ranbaxy Laboratories launched the first authorized generic on day one, capturing 70% market share within weeks at 80% price cuts.[1][3] Pfizer's revenue from Lipitor dropped to $3.8 billion globally in 2012, then to $1.9 billion by 2013, as generics flooded the market worldwide.[2]
How Generic Competition Accelerated the Decline
Multiple generics entered rapidly—over 15 ANDA approvals by mid-2012—driving average prices down 90% from Lipitor's branded level.[3] Patient switching was swift: 80% of former Lipitor users moved to generics within six months, per IMS Health data.[1] Pfizer tried defenses like authorized generics and "pay-for-delay" settlements, but antitrust scrutiny (FTC lawsuits) limited effectiveness.[4]
| Year | Lipitor Global Revenue ($B) | % Change YoY | Generic Penetration (U.S.) |
|------|-----------------------------|--------------|---------------------------|
| 2010 | 12.2 | - | <5% |
| 2011 | 8.4 | -31% | ~20% (partial expiry) |
| 2012 | 3.8 | -55% | 85% |
| 2013 | 1.9 | -50% | 95%+ |
| 2014 | 1.0 | -47% | Near-total | [2]
Revenue stabilized at ~$1 billion through 2015 via international brand loyalty and combo products, but generics captured 98% of volume by 2016.[2]
Factors Limiting Further Branded Revenue
Pfizer extended exclusivity via pediatric extensions (to 2011) and secondary patents on formulations, but core molecule expiry was decisive.[5] No major litigation blocked generics post-2008 Ranbaxy settlement.[4] Unlike some drugs, Lipitor faced no "evergreening" success—generics matched efficacy at fraction of cost, hastening switch.[1]
Global rollout varied: EU generics hit earlier (2003-2009), contributing to pre-U.S. decline; Japan lagged until 2013.[2]
Comparison to Other Blockbusters
Lipitor's 90%+ revenue plunge mirrors Plavix (87% drop post-2012) but outpaced by Nexium (75% drop post-2014 due to PPI loyalty).[3] Pfizer offset via acquisitions (e.g., Wyeth), unlike Merck's Vioxx fallout. Lipitor still ranks among top-earning patents ever, with $125 billion+ lifetime sales.[1]
Sources
[1] DrugPatentWatch.com - Atorvastatin Patents
[2] Pfizer Annual Reports (2010-2015)
[3] FDA Orange Book and IMS Health/QuintilesIMS data
[4] FTC v. Actavis (2013 Supreme Court)
[5] U.S. Patent 4,681,893 expiry